Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Limited clinical relevance of mitochondrial DNA mutation and gene expression analyses in ovarian cancer.

Bragoszewski P, Kupryjanczyk J, Bartnik E, Rachinger A, Ostrowski J.

BMC Cancer. 2008 Oct 8;8:292. doi: 10.1186/1471-2407-8-292.

2.

Altered expression of 12S/MT-RNR1, MT-CO2/COX2, and MT-ATP6 mitochondrial genes in prostate cancer.

Abril J, de Heredia ML, González L, Clèries R, Nadal M, Condom E, Aguiló F, Gómez-Zaera M, Nunes V.

Prostate. 2008 Jul 1;68(10):1086-96. doi: 10.1002/pros.20771.

PMID:
18409190
3.

High incidence of somatic mitochondrial DNA mutations in human ovarian carcinomas.

Liu VW, Shi HH, Cheung AN, Chiu PM, Leung TW, Nagley P, Wong LC, Ngan HY.

Cancer Res. 2001 Aug 15;61(16):5998-6001.

4.

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.

Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD 2nd, Abkevich V, Potter J, Pruss D, Glenn P, Li Y, Li J, Gonzalez-Angulo AM, McCune KS, Markman M, Broaddus RR, Lanchbury JS, Lu KH, Mills GB.

J Clin Oncol. 2010 Aug 1;28(22):3570-6. doi: 10.1200/JCO.2009.27.2997. Epub 2010 Jul 6.

5.

Evidence for the presence of somatic mitochondrial DNA mutations in right atrial appendage tissues of coronary artery disease patients.

Matam K, Shaik NA, Aggarwal S, Diwale S, Banaganapalli B, Al-Aama JY, Elango R, Rao P, Hasan Q.

Mol Genet Genomics. 2014 Aug;289(4):533-40. doi: 10.1007/s00438-014-0828-2. Epub 2014 Mar 7.

PMID:
24604425
6.

Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.

Concin N, Hofstetter G, Berger A, Gehmacher A, Reimer D, Watrowski R, Tong D, Schuster E, Hefler L, Heim K, Mueller-Holzner E, Marth C, Moll UM, Zeimet AG, Zeillinger R.

Clin Cancer Res. 2005 Dec 1;11(23):8372-83.

7.

Expression of mitochondrial genes MT-ND1, MT-ND6, MT-CYB, MT-COI, MT-ATP6, and 12S/MT-RNR1 in colorectal adenopolyps.

Wallace L, Mehrabi S, Bacanamwo M, Yao X, Aikhionbare FO.

Tumour Biol. 2016 Sep;37(9):12465-12475. Epub 2016 Jun 22.

PMID:
27333991
8.

Mitochondrial DNA mutations in pancreatic cancer.

Kassauei K, Habbe N, Mullendore ME, Karikari CA, Maitra A, Feldmann G.

Int J Gastrointest Cancer. 2006;37(2-3):57-64.

PMID:
17827523
9.

Mitochondrial mutations are associated with atherosclerotic lesions in the human aorta.

Sobenin IA, Sazonova MA, Postnov AY, Bobryshev YV, Orekhov AN.

Clin Dev Immunol. 2012;2012:832464. Epub 2012 Sep 11.

10.

Extensive screening system using suspension array technology to detect mitochondrial DNA point mutations.

Nishigaki Y, Ueno H, Coku J, Koga Y, Fujii T, Sahashi K, Nakano K, Yoneda M, Nonaka M, Tang L, Liou CW, Paquis-Flucklinger V, Harigaya Y, Ibi T, Goto Y, Hosoya H, DiMauro S, Hirano M, Tanaka M.

Mitochondrion. 2010 Apr;10(3):300-8. doi: 10.1016/j.mito.2010.01.003. Epub 2010 Jan 11.

PMID:
20064630
11.

Mitochondrial DNA mutations in breast cancer tissue and in matched nipple aspirate fluid.

Zhu W, Qin W, Bradley P, Wessel A, Puckett CL, Sauter ER.

Carcinogenesis. 2005 Jan;26(1):145-52. Epub 2004 Sep 16.

PMID:
15375011
12.

Clinical value of mitochondrial mutations in colorectal cancer.

Lièvre A, Chapusot C, Bouvier AM, Zinzindohoué F, Piard F, Roignot P, Arnould L, Beaune P, Faivre J, Laurent-Puig P.

J Clin Oncol. 2005 May 20;23(15):3517-25.

PMID:
15908662
13.

[Alterations of mitochondrial DNA in ovarian cancer patients with and without chemotherapy].

Shi HH, Pan LY, Yang XY, Yuan Y, Yu XD.

Zhonghua Fu Chan Ke Za Zhi. 2005 Jul;40(7):469-71. Chinese.

PMID:
16080874
14.

[Mutations in the D-loop region of mitochondrial DNA in ovarian tumors].

Shi HH, Vincent L, Hextan N, Yang XY.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2002 Apr;24(2):170-3. Chinese.

PMID:
12905796
15.

Somatic mitochondrial DNA mutations in primary and metastatic ovarian cancer.

Van Trappen PO, Cullup T, Troke R, Swann D, Shepherd JH, Jacobs IJ, Gayther SA, Mein CA.

Gynecol Oncol. 2007 Jan;104(1):129-33. Epub 2006 Aug 30.

PMID:
16942794
16.

Genetic aetiology of ophthalmological manifestations in children - a focus on mitochondrial disease-related symptoms.

Widgren P, Hurme A, Falck A, Keski-Filppula R, Remes AM, Moilanen J, Majamaa K, Kervinen M, Uusimaa J.

Acta Ophthalmol. 2016 Feb;94(1):83-91. doi: 10.1111/aos.12897. Epub 2015 Oct 8.

17.

Significance of somatic mutations and content alteration of mitochondrial DNA in esophageal cancer.

Tan DJ, Chang J, Liu LL, Bai RK, Wang YF, Yeh KT, Wong LJ.

BMC Cancer. 2006 Apr 18;6:93.

18.

Absence of p51 alteration in human ovarian cancer.

Shinozaki H, Okamoto A, Shimizu K, Saito M, Yokota J, Ochiai K.

Int J Oncol. 2001 Mar;18(3):549-52.

PMID:
11179485
19.

Mitochondrial DNA alterations in colorectal cancer cell lines.

Chihara N, Amo T, Tokunaga A, Yuzuriha R, Wolf AM, Asoh S, Suzuki H, Uchida E, Ohta S.

J Nippon Med Sch. 2011;78(1):13-21.

20.

Increased Incidence of Mitochondrial Cytochrome C Oxidase 1 Gene Mutations in Patients with Primary Ovarian Insufficiency.

Zhen X, Wu B, Wang J, Lu C, Gao H, Qiao J.

PLoS One. 2015 Jul 30;10(7):e0132610. doi: 10.1371/journal.pone.0132610. eCollection 2015.

Supplemental Content

Support Center